BioSpace News Archive

Continued support of existing investors will fund commercialization efforts, product launch later this year

Graminex® L.L.C., producer of Graminex® Non-Solvent Flower Pollen Extracts™, receives Health Canada Approval under the Natural and Non-prescription Health Products Directorate for its PollenBerry® Flower Pollen Extract™.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and LakePharma, Inc., the leading US-based biologics CRDMO, today announced a strategic collaboration to offer antibody discovery and development solutions to pharmaceutical and biotechnology customers.

Spheryx introduces xSight with live demonstrations at a leading international conference on protein-based therapeutics. The technology meets a critical industry need for the detection and characterization of protein aggregates, a safety hazard in biologic pharmaceuticals.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that the Company completed an at-the-market offering for $5.3 million in gross proceeds, with insiders responsible for supporting over 37% of the raise.

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, is proud to join the LGBTQ community in celebrating the 2019 LGBTQ Pride season through its participation in 24 Pride events across the country—in many locations, touring with its “Our Champions” Pride bus.

Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration has extended the review period for the New Drug Application of quizartinib, an investigational FLT3 inhibitor, currently under Priority Review for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia.

The Annual NaBITA Conference is the leading conference in the field of higher education threat assessment and behavioral intervention.

The North Carolina Mesothelioma Victims Center says, “We are now urging a person with mesothelioma or asbestos exposure lung cancer anywhere in North Carolina or their family to call us anytime at 800-714-0303.

The adoption of a unique combination of the best in science and health technology such as genomics, biomarkers and companion technologies are expected to be the biopharmaceutical industry’s new growth machine, according to new research from Accenture (NYSE: ACN).